ArticlePloS one2013
Type-specific human papillomavirus biological features: validated model-based estimates.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 29 citations in OpenAlex.
- Trial
- Prevalence and genotype distribution of human papillomavirus infection among Kurdish people, Iran.SAGE open medicine · 2025Article
- Leveraging single-dose human papillomavirus vaccination dose-efficiency to attain cervical cancer elimination in resource-constrained settings.Journal of the National Cancer Institute. Monographs · 2024Article
- Concomitant human papillomavirus (HPV) vaccination and screening for elimination of HPV and cervical cancer.Nature communications · 2024Article
- Article
- Evidence-based impact projections of single-dose human papillomavirus vaccination in India: a modelling study.The Lancet. Oncology · 2022Article
- On the Elimination of Infections Related to Oncogenic Human Papillomavirus: An Approach Using a Computational Network Model.Viruses · 2021Article
- Vaccination With Moderate Coverage Eradicates Oncogenic Human Papillomaviruses If a Gender-Neutral Strategy Is Applied.The Journal of infectious diseases · 2020Article
- Revisiting assumptions about age-based mixing representations in mathematical models of sexually transmitted infections.Vaccine · 2018Article
- Impacts of human papillomavirus vaccination for different populations: A modeling study.International journal of cancer · 2018Article
- [Trajectory modeling for estimating the trend of human papillomavirus infection status among men who have sex with men].Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2018Article
- Different Challenges in Eliminating HPV16 Compared to Other Types: A Modeling Study.The Journal of infectious diseases · 2017Article
- Human Papillomavirus Vaccination at a Time of Changing Sexual Behavior.Emerging infectious diseases · 2016Article
- The role of acquired immunity in the spread of human papillomavirus (HPV): explorations with a microsimulation model.PloS one · 2015Article
- Upscaling human papillomavirus vaccination in high-income countries: impact assessment based on transmission model.Infectious agents and cancer · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 3 countries.
Funding
Abstract
Infection with high-risk (hr) human papillomavirus (HPV) is considered the necessary cause of cervical cancer. Vaccination against HPV16 and 18 types, which are responsible of about 75% of cervical cancer worldwide, is expected to have a major global impact on cervical cancer occurrence. Valid estimates of the parameters that regulate the natural history of hrHPV infections are crucial to draw reliable projections of the impact of vaccination. We devised a mathematical model to estimate the probability of infection transmission, the rate of clearance, and the patterns of immune response following the clearance of infection of 13 hrHPV types. To test the validity of our estimates, we fitted the same transmission model to two large independent datasets from Italy and Sweden and assessed finding consistency. The two populations, both unvaccinated, differed substantially by sexual behaviour, age distribution, and study setting (screening for cervical cancer or Chlamydia trachomatis infection). Estimated transmission probability of hrHPV types (80% for HPV16, 73%-82% for HPV18, and above 50% for most other types); clearance rates decreasing as a function of time since infection; and partial protection against re-infection with the same hrHPV type (approximately 20% for HPV16 and 50% for the other types) were similar in the two countries. The model could accurately predict the HPV16 prevalence observed in Italy among women who were not infected three years before. In conclusion, our models inform on biological parameters that cannot at the moment be measured directly from any empirical data but are essential to forecast the impact of HPV vaccination programmes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.